Spruce Biosciences (SPRB) Assets Average (2020 - 2026)
Spruce Biosciences (SPRB) posted quarterly Assets Average of $54.6 million for Q1 2026, up 42.06% year-over-year from $38.4 million in Q1 2025, and up 59.78% quarter-over-quarter from $34.2 million in Q4 2025.
Spruce Biosciences (SPRB) Assets Average (2020 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Assets Average for 7 consecutive years, with $54.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 42.06% year-over-year to $54.6 million; the TTM figure through Mar 2026 stood at $54.6 million (up 42.06% YoY), while the FY2025 annual figure was $49.1 million, down 34.14% from the prior year.
- Assets Average grew to $54.6 million in Q1 2026 per SPRB's latest filing, from $34.2 million in the prior quarter.
- Across five years, Assets Average topped out at $132.5 million in Q2 2023 and bottomed at $18.6 million in Q3 2025.
- Historically, Assets Average has averaged $80.5 million across 5 years, with a median of $90.5 million in 2022.
- Annual changes were most pronounced in 2025 — Assets Average slumped 73.59% — and 2026, when it soared 42.06%.
- Spruce Biosciences' Assets Average stood at $90.5 million in 2022, then rose by 19.89% to $108.5 million in 2023, then tumbled by 49.15% to $55.2 million in 2024, then tumbled by 38.05% to $34.2 million in 2025, then surged by 59.78% to $54.6 million in 2026.
- Business Quant data shows SPRB's Assets Average at $54.6 million in Q1 2026, $34.2 million in Q4 2025, and $18.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | 79.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 79.51 Mn |
| Mar 31, 2026 | 54.59 Mn |
| Dec 31, 2025 | 34.17 Mn |
| Sep 30, 2025 | 18.57 Mn |
| Jun 30, 2025 | 26.73 Mn |
| Mar 31, 2025 | 38.43 Mn |
| Dec 31, 2024 | 55.16 Mn |
| Sep 30, 2024 | 70.31 Mn |
| Jun 30, 2024 | 81.53 Mn |
| Mar 31, 2024 | 95.74 Mn |
| Dec 31, 2023 | 108.47 Mn |
| Sep 30, 2023 | 119.47 Mn |
| Jun 30, 2023 | 132.54 Mn |
| Mar 31, 2023 | 112.38 Mn |
| Dec 31, 2022 | 90.47 Mn |
| Sep 30, 2022 | 99.91 Mn |
| Jun 30, 2022 | 109.75 Mn |
| Mar 31, 2022 | 120.74 Mn |
| Dec 31, 2021 | 130.79 Mn |
| Sep 30, 2021 | 139.27 Mn |